Posted by Michael Wonder on 02 Nov 2020
Janssen submits paliperidone palmitate 6 month supplemental new drug application to U.S. FDA for treatment of schizophrenia in adults
2 November 2020 - If approved, paliperidone palmitate 6 month will be the first and only long-acting injectable schizophrenia treatment with a twice-yearly dosing regimen.
Janssen today announced the submission of a supplemental new drug application to the U.S. FDA for paliperidone palmitate 6 month for the treatment of adults diagnosed with schizophrenia.
If approved, paliperidone palmitate 6 month will be the first and only long-acting injectable schizophrenia medication with a twice-yearly dosing regimen.
